高级检索
当前位置: 首页 > 详情页

Protocol for a Pragmatic Trial of Pharmacotherapy Options Following Unsatisfactory Initial Treatment in OCD (PROCEED).

| 导出 | |

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE ◇ SSCI

机构: [1]Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China. [2]Department of Psychiatry, The Second Affiliated Hospital of Xinxiang Medical University, Henan, China. [3]Mental Health Center, General Hospital of Ningxia Medical University, Ningxia, China. [4]Psychiatry Department, The First Affiliated Hospital of Nanchang University, Jiangxi, China. [5]Guizhou Provincial People's Hospital, Guizhou, China. [6]Mental Health Center, West China Hospital, The Sichuan University, Sichuan, China. [7]Department of Medical Psychology, The Affiliated Brain Hospital of Nanjing Medical University, Nanjing, China. [8]Hangzhou Seventh People's Hospital, Mental Health Center Zhejiang University School of Medicine, Zhejiang, China. [9]The First Psychiatric Hospital of Harbin, Heilongjiang, China. [10]Department of Psychiatry, The First Affiliated Hospital of Jinan University, Guangzhou, China. [11]Wuhan Mental Health Center, Hubei, China. [12]First Affiliated Hospital of Kunming Medical University, Kunming, China. [13]Suzhou Guangji Hospital, Jiangsu, China. [14]Department of Psychiatry, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, United States. [15]Department of Psychiatry and South African Medical Research Council Unit on Risk & Resilience in Mental Disorders, University of Cape Town, Cape Town, South Africa. [16]Institute of Psychological and Behavioral Science, Shanghai Jiao Tong University, Shanghai, China.
出处:
ISSN:

关键词: obsessive-compulsive disorder treatment-naïve pharmacotherapy alternatives remission

摘要:
Selective serotonin reuptake inhibitors (SSRIs) are the first-line pharmacotherapy for obsessive-compulsive disorder (OCD), but a large proportion of patients do not achieve remission after an adequate SSRI trial. To the best of our knowledge, there have been no well-powered randomized controlled trials (RCTs) of sequenced pharmacotherapy using pragmatic research designs. China provides a unique context for undertaking such a trial that will recruit the largest treatment-naïve participants and systematically compare the efficacy of different sequenced pharmacotherapy.A pragmatic research design will be adopted, with n = 1,600 treatment-naïve OCD patients initially treated for sertraline for 12 weeks, and with non-remitters then randomized to 5 different augmentation or switching pharmacotherapy options for another 12 weeks. The 5 arms will include: (1) treatment with higher than usual doses of sertraline, (2) switch to fluvoxamine, (3) switch to venlafaxine, (4) augmentation with memantine, and (5) augmentation with aripiprazole.China is uniquely positioned to recruit sufficiently large sample sizes of treatment-naïve OCD patients to compare different pharmacotherapy options; data from the proposed trial promises to help inform current clinical practice guidelines by providing important information about optimal pharmacotherapy choice for those who demonstrate no response or response but no remission to first line pharmacotherapy.The trail was registered on 27 August 2020 in ClinicalTrials.gov (https://register.clinicaltrials.gov/) (NCT04539951).Copyright © 2022 Wang, Gu, Gao, Wang, Fang, Hu, Xiang, Li, Liu, Tang, Wang, Jia, Li, Cheng, Tang, Simpson, Stein and Wang.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2023]版:
大类 | 3 区 医学
小类 | 3 区 精神病学
最新[2023]版:
大类 | 3 区 医学
小类 | 3 区 精神病学
JCR分区:
出版当年[2022]版:
Q2 PSYCHIATRY
最新[2023]版:
Q2 PSYCHIATRY

影响因子: 最新[2023版] 最新五年平均 出版当年[2022版] 出版当年五年平均 出版前一年[2021版] 出版后一年[2023版]

第一作者:
第一作者机构: [1]Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
通讯作者:
通讯机构: [1]Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China. [16]Institute of Psychological and Behavioral Science, Shanghai Jiao Tong University, Shanghai, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:53621 今日访问量:0 总访问量:1665 更新日期:2024-11-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 昆明医科大学第一附属医院 技术支持:重庆聚合科技有限公司 地址:云南省昆明市西昌路295号(650032)